



Final Appraisal Recommendation

Advice number: 0125 – May 2025

Ziconotide (Prialt®) 100 micrograms/ml solution for intrathecal infusion

Resubmission by Esteve Pharmaceuticals Ltd.

Recommendation of the All Wales Medicines Strategy Group

Ziconotide (Prialt®) is recommended as an option for use in NHS Wales for the treatment of severe chronic pain in adults who require intrathecal analgesia.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional notes:

- AWMSG considered ziconotide under the AWMSG policy for appraising medicines for severe conditions.
- This advice replaces the AWMSG recommendation previously issued in July 2008 (AWTTC reference number 335).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5385), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0125:
Ziconotide (Prialt®) 100 micrograms/ml solution for intrathecal infusion
May 2025